Yesterday, UCB hosted an R&D call to highlight the phase 2a data for galvokimig from EADV 2025, which showed strong efficacy in atopic dermatitis (AD), with a 52.6% placebo-adjusted EASI75 response at week 12, outperforming other biologics in cross-trial comparison. The KOL highlighted galvokimig's potential for broad positioning across the AD treatment paradigm if the early data is replicated in later stage trials, especially as a monotherapy. We update our model for UCB, which brings us to a n...
In UCB related news, MoonLake Therapeutics (no coverage) reported topline phase 3 data for Bimzelx competitor, sonelokimab (IL-17A/F nanobody) in hidradenitis suppurativa (HS) that showed mixed results. Averaging both VELA-1 and VELA-2 trials brings us to a 13.5% placebo adjusted HiSCR75 response, which is lower than the 17.5% that Bimzelx showed in BE HEARD I and II, and the approx. 20% delta bar set by MoonLake's management earlier this year. Acknowledging the high placebo response in VELA-2, ...
Aedifica: €21m investment in the development of 3 care homes in Finland. CTP: Highlights from 2-day CMD in Germany. dsm-firmenich: Softly does it. Prosus: Expanding the ecosystem. Randstad: Preliminary preview 3Q25F results due 22 October. TKH Group: Change is coming. UCB: Renewed tariff threat on US branded pharma unlikely to affect UCB
Ackermans & van Haaren invests 22 million euros in VKC Nuts Dear shareholder, Dear Madam, Dear Sir, Ackermans & van Haaren (AvH) has entered into an agreement to invest 22 million euros in VKC Nuts Private Limited (VKC Nuts), a leading family business in the fast-growing nuts and dried fruits sector in India. Upon closing of this investment, which is expected in the fourth quarter of this year, AvH will hold a 16.6% stake in VKC Nuts and be represented on its board of directors. Please find attached the full press release. Best regards Ackermans & van Haaren Attachment ...
Ackermans & van Haaren investit 22 millions d'euros dans VKC Nuts Cher actionnaire, Monsieur, Madame, Ackermans & van Haaren (AvH) a conclu un accord en vue d’investir 22 millions d’euros dans VKC Nuts Private Limited (VKC Nuts), une entreprise familiale leader du marché dans le secteur en forte croissance des fruits à coque et fruits secs en Inde. À l’issue de cette opération, dont le closing est attendu au quatrième trimestre de cette année, AvH détiendra une participation de 16,6 % dans VKC Nuts et sera représentée au sein de son conseil d’administration. Veuillez trouver ci-joint l...
Ackermans & van Haaren investeert 22 miljoen euro in VKC Nuts Geachte aandeelhouder, Geachte mevrouw, geachte heer, Ackermans & van Haaren (AvH) heeft een overeenkomst gesloten om 22 miljoen euro te investeren in VKC Nuts Private Limited (VKC Nuts), een toonaangevende familiale onderneming op de snelgroeiende Indiase markt voor noten en gedroogd fruit. Na afronding van deze investering, die wordt verwacht in het vierde kwartaal van dit jaar, zal AvH een belang van 16,6% verwerven in VKC Nuts en vertegenwoordigd zijn in de raad van bestuur. Gelieve bijgevoegd het volledige persbericht t...
KBC Securities will host its annual life sciences conference on 25 September in Brussels. The event will include 14 exciting companies, both public and private, from the BeNeLux ecosystem and beyond. In this conference note, we provide an overview of the attending companies, as well as an outlook on KBC Securities' life sciences broader coverage.
ARGAN: S&P MAINTAINED THE “INVESTMENT GRADE” STATUS WITH A “BBB-” RATING AND A “STABLE” OUTLOOK Presse release – Neuilly-sur-Seine, Wednesday, September 24, 2025 – 8.30 am ARGAN: S&P maintained the “Investment Grade” status with a “BBB-” rating and a “stable” outlook Following the press release1 indicating the withdrawal of the CARAT portfolio from the market by ARGAN, S&P Global Ratings published a bulletin stating that it considers ARGAN’s level of indebtedness to be consistent with its current rating, namely a long-term issuer rating of 'BBB-' with a 'Stable' outlook. The bulletin ...
ARGAN : S&P MAINTIENT LE STATUT « INVESTMENT GRADE » AVEC UNE NOTE « BBB- » ET UNE PERSPECTIVE « STABLE » Communiqué de presse – Neuilly-sur-Seine, mercredi 24 septembre 2025 – 8h30 ARGAN : S&P maintient le statut « Investment Grade » avec une note « BBB- » et une perspective « stable » Suite au communiqué de presse1 indiquant le retrait du marché du portefeuille CARAT par ARGAN, S&P Global Ratings a publié un bulletin de note précisant juger le niveau d’endettement d’ARGAN en adéquation avec la notation actuelle, à savoir une note émetteur long terme « BBB- » avec une perspective « St...
Last week’s EPRA conference provided cautious optimism on listed European real estate. The segment offers a mix of risks and opportunities, with discounted valuations presenting attractive entry points. We downgrade Care Property Invest (Underperform vs Neutral, TP €12 vs €13.5); we lower our TPs for British Land, Landsec, Shurgard, and Xior Student Housing; we raise our TPs for URW, Wereldhave and VGP. In conclusion we favour logistics, retail, Spain, and CEE for growth, and Switzerland remains...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.